Your browser doesn't support javascript.
loading
Biomimetic cell-derived nanocarriers in cancer research.
Soprano, Enrica; Polo, Ester; Pelaz, Beatriz; Del Pino, Pablo.
Afiliación
  • Soprano E; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15705, Santiago de Compostela, Spain.
  • Polo E; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15705, Santiago de Compostela, Spain. ester.polo@usc.es.
  • Pelaz B; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15705, Santiago de Compostela, Spain. beatriz.pelaz@usc.es.
  • Del Pino P; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15705, Santiago de Compostela, Spain. pablo.delpino@usc.es.
J Nanobiotechnology ; 20(1): 538, 2022 Dec 22.
Article en En | MEDLINE | ID: mdl-36544135
Nanoparticles have now long demonstrated capabilities that make them attractive to use in biology and medicine. Some of them, such as lipid nanoparticles (SARS-CoV-2 vaccines) or metallic nanoparticles (contrast agents) are already approved for their use in the clinic. However, considering the constantly growing body of different formulations and the huge research around nanomaterials the number of candidates reaching clinical trials or being commercialized is minimal. The reasons behind being related to the "synthetic" and "foreign" character of their surface. Typically, nanomaterials aiming to develop a function or deliver a cargo locally, fail by showing strong off-target accumulation and generation of adverse responses, which is connected to their strong recognition by immune phagocytes primarily. Therefore, rendering in negligible numbers of nanoparticles developing their intended function. While a wide range of coatings has been applied to avoid certain interactions with the surrounding milieu, the issues remained. Taking advantage of the natural cell membranes, in an approach that resembles a cell transfer, the use of cell-derived surfaces has risen as an alternative to artificial coatings or encapsulation methods. Biomimetic technologies are based on the use of isolated natural components to provide autologous properties to the nanoparticle or cargo being encapsulated, thus, improving their therapeutic behavior. The main goal is to replicate the (bio)-physical properties and functionalities of the source cell and tissue, not only providing a stealthy character to the core but also taking advantage of homotypic properties, that could prove relevant for targeted strategies. Such biomimetic formulations have the potential to overcome the main issues of approaches to provide specific features and identities synthetically. In this review, we provide insight into the challenges of nano-biointerfaces for drug delivery; and the main applications of biomimetic materials derived from specific cell types, focusing on the unique strengths of the fabrication of novel nanotherapeutics in cancer therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Materiales Biomiméticos / Nanopartículas / COVID-19 / Neoplasias Límite: Humans Idioma: En Revista: J Nanobiotechnology Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Materiales Biomiméticos / Nanopartículas / COVID-19 / Neoplasias Límite: Humans Idioma: En Revista: J Nanobiotechnology Año: 2022 Tipo del documento: Article País de afiliación: España